Serotonin as a mediator of cyclic flow variations in stenosed canine coronary arteries.
- 1 March 1986
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 73 (3) , 572-578
- https://doi.org/10.1161/01.cir.73.3.572
Abstract
The data obtained in this study demonstrate that the concentration of serotonin is markedly elevated (18- to 27-fold) at the site of a coronary arterial stenosis in open-chest, anesthetized dogs with cyclic flow variations. Cyclic flow variations in this experimental preparation were abolished by ketanserin, a 5-hydroxytryptamine antagonist, but serotonin concentration at the site of the coronary stenosis remained elevated. The intra-atrial administration of serotonin (0.16 to 1 mg/min) restored cyclic flow variations after they had been abolished by ketanserin. Taken together, these data suggest that serotonin may be one of the important mediators of cyclic flow variations in this experimental preparation.This publication has 17 references indexed in Scilit:
- Platelet-vessel wall interactions: Implication of 5-hydroxytryptamine. A reviewInflammation Research, 1984
- Antagonism by ketanserin of 5-HT-induced vasoconstriction unmasks a 5-HT-induced vasodilationEuropean Journal of Pharmacology, 1984
- Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries.Circulation, 1984
- Interaction of ketanserin and its metabolite ketanserinol with 5HT2 receptors in pulmonary and coronary arteries of calfNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1984
- 5-HT2 receptor blockade to study serotonin-induced pathologyTrends in Pharmacological Sciences, 1983
- Mechanism of the Hypotensive Effect of KetanserinJournal of Cardiovascular Pharmacology, 1982
- Inhibition of 5-hydroxytryptamine-induced and-amplified human platelet aggregation by ketanserin (R 41 468), a selective 5-HT2-receptor antagonistInflammation Research, 1982
- Receptor binding profile of R 41 468, A novel antagonist at 5-HT2 receptorsLife Sciences, 1981
- Secretable Storage Pools in PlateletsAnnual Review of Medicine, 1979
- Platelet aggregation in partially obstructed vessels and its elimination with aspirin.Circulation, 1976